Skip to content

Search

New childhood brain tumour drugs to be tested

It is the kids he treats in his role as a paediatric oncologist that motivate Dr Nick Gottardo in his work as a The Kids Research Institute Australia cancer researcher.

Dad’s Dream Inspires Global Cancer Fight

The Global Symposium on Childhood Brain Tumours is bringing the world's premier childhood brain tumour researchers and scientists together in Perth.

Research sheds new light on childhood Leukaemia treatment

A The Kids study examining drug resistance in leukaemia patients has shed new light on why some treatments may be more effective than others.

Global Assault on Childhood Brain Tumours Gains Momentum

A report outlining key steps to tackle a common and aggressive childhood brain tumor is gaining rapid momentum after attracting international attention.

Ethan's brain cancer battle inspires research

A new research scholarship to combat childhood brain tumours will be launched tonight in honour of two year old Perth toddler Ethan Davies.

Researchers find genetic clue to cancer relapse

Cancer researchers at The Kids for Child Health Research have developed a new test that can rapidly detect the loss of genes in cancer cells.

Exposure to diagnostic radiological procedures and the risk of childhood acute lymphoblastic leukemia

Diagnostic irradiation of the mother during pregnancy increases the risk of childhood acute lymphoblastic leukemia

First Nations Childhood Cancer Research

A first of its kind research program at The Kids Research Institute Australia aims to develop new strategies to better treat Aboriginal and Torres Strait Islander children with cancer.

Efficacy of DYRK1A inhibitors in novel models of Down syndrome acute lymphoblastic leukemia

Despite significant advances, outcomes for children with Down syndrome (DS, trisomy 21) who develop acute lymphoblastic leukemia remain poor. Reports of large DS-ALL cohorts have shown that children with DS have inferior event-free survival and overall survival compared to children without DS.

EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses

High-grade gliomas including glioblastoma (GBM) and diffuse midline gliomas (DMG) represent the most lethal and aggressive brain cancers where current treatment modalities offer limited efficacy. Chimeric antigen receptor (CAR) T cell therapies have emerged as a promising strategy, boasting tumor-specific targeting and the unique ability to penetrate the blood-brain barrier.